Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec;191(5):748-754.
doi: 10.1111/bjh.16695. Epub 2020 May 12.

Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy

Hassan Sibai  1   2 , Ruiqi Chen  1   2 , Xing Liu  1   3 , Umberto Falcone  1   2 , Aaron Schimmer  1   2 , Andre Schuh  1   2 , Arjun Law  1   2 , Caroline McNamara  1   2 , Dawn Maze  1   2 , Karen Yee  1   2 , Mark Minden  1   2 , Steven M Chan  1   2 , Vikas Gupta  1   2 , Tracy Murphy  1   2 , Naoko Sakurai  1 , Eshetu G Atenafu  3 , Joseph M Brandwein  4 , Jack T Seki  1   5   6
Affiliations
Clinical Trial

Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy

Hassan Sibai et al. Br J Haematol. 2020 Dec.

Abstract

Venous thromboembolism (VTE) is a well-known complication in adults receiving asparaginase (ASNase)-based intensification chemotherapy for acute lymphoblastic leukaemia (ALL). The optimal preventative strategy is unclear. Our objective is to determine the effects of low-molecular-weight heparin (LMWH) as primary VTE prophylaxis. A single-centred retrospective cohort study of adult patients with Philadelphia chromosome negative (Ph-) ALL who received ASNase-based intensification from 2001 to 2017, with prophylaxis given from 2011 to 2017. In all, 214 patients were included in this study with 99 in the historical control group and 125 in the prophylaxis group. The mean (range) enoxaparin dose was 0·79 (0·39-1·2) mg/kg. Of the 125 patients in the prophylaxis group 17 (13·6%) developed VTE during the intensification phase, while 27/99 patients (27·3%) in the control cohort experienced at least one thrombotic event (odds ratio [OR] 0·42, 95% confidence interval [CI] 0·21-0·83). Overall, the main sites of VTE incidences included deep vein thrombosis in the lower extremity (54·6%), pulmonary embolism (13·6%) and catheter-related thrombosis (22·7%). In addition, we found that after adjusting for age, T-phenotype ALL was associated with VTE development (OR 3·07, 95% CI 1·04-9·08). There was no documented major bleeding in the prophylaxis group. LMWH prophylaxis reduced the incidence of symptomatic VTE in adult patients with ALL receiving intensification chemotherapy with ASNase.

Keywords: acute lymphoblastic leukemia; anticoagulation; thrombosis.

PubMed Disclaimer

References

    1. Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27:553-9.
    1. De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Haemostatic alterations induced by treatment with s and clinical consequences. Thromb Haemost. 2015;113:247-61.
    1. Staddon JH, Smock KJ, Schiffman JD, Fluchel MN, Engel ME, Weyrich AS, et al. Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma. Blood Coagul Fibrinolysis. 2015;26:840-3.
    1. Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Jennie YL, et al. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. J Oncol Pharm Practice. 2019;1-19. https://doi.org/10.1177/1078155219838316
    1. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, De Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 perspective studies comprising 1752 pediatric patients. Blood. 2006;108:2216-22.

Publication types

LinkOut - more resources